

TriSalus Life Sciences secured FDA clearance for its TriNav Advance device, but shares face critical resistance levels amid a recent slide.
You can purchase shares of TriSalus Life Sciences (NASDAQ:TLSI) through any online brokerage.
Other companies in TriSalus Life Sciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
TriSalus Life Sciences has a consensus price target of $10.72.
The stock price for TriSalus Life Sciences (NASDAQ: TLSI) is $3.89 last updated November 4, 2026 at 5:05 PM EST.
There are no upcoming dividends for TriSalus Life Sciences.
TriSalus Life Sciences does not have any upcoming earnings scheduled.
There is no upcoming split for TriSalus Life Sciences.
TriSalus Life Sciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist,...